MX9704043A - Surtido de farmaco de liberacion sostenida empleando una goma de hidrocoloide en polvo obtenible a partir de plantas superiores. - Google Patents

Surtido de farmaco de liberacion sostenida empleando una goma de hidrocoloide en polvo obtenible a partir de plantas superiores.

Info

Publication number
MX9704043A
MX9704043A MX9704043A MX9704043A MX9704043A MX 9704043 A MX9704043 A MX 9704043A MX 9704043 A MX9704043 A MX 9704043A MX 9704043 A MX9704043 A MX 9704043A MX 9704043 A MX9704043 A MX 9704043A
Authority
MX
Mexico
Prior art keywords
higher plants
percent
sustained
drug delivery
release drug
Prior art date
Application number
MX9704043A
Other languages
English (en)
Other versions
MXPA97004043A (es
Inventor
Eric H Kuhrts
David R Friend
Syed A Altaf
Karen Yu
Jagdish Parasrampuria
Original Assignee
Cibus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cibus Pharmaceuticals Inc filed Critical Cibus Pharmaceuticals Inc
Publication of MXPA97004043A publication Critical patent/MXPA97004043A/es
Publication of MX9704043A publication Critical patent/MX9704043A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composicion farmacéutica de surtido oral para obtener liberacion sostenida de un fármaco en un mamífero; la composicion incluye (a) una cantidad adecuada de una goma hidrocoloide aceptable farmacéuticamente obtenible de plantas superiores (por ejemplo, aproximadamente 20% - 90% en peso), (b) otro excipiente (por ejemplo, aproximadamente 5% - 30% en peso) que ayuda en la liberacion sostenida y (c) una cantidad efectiva terapéuticamente de un fármaco; preferiblemente el tamaño de partícula medio de la goma es de aproximadamente 150æ o menos; se describe también un procedimiento para preparar la composicion y un método para obtener liberacion sostenida de un fármaco administrando la composicion a un sujeto en necesidad del mismo.
MX9704043A 1994-12-01 1995-11-30 Surtido de farmaco de liberacion sostenida empleando una goma de hidrocoloide en polvo obtenible a partir de plantas superiores. MX9704043A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34851594A 1994-12-01 1994-12-01
US348515 1994-12-01
PCT/US1995/015593 WO1996016638A1 (en) 1994-12-01 1995-11-30 Sustained-release drug delivery employing a powdered hydrocolloid gum obtainable from higher plants

Publications (2)

Publication Number Publication Date
MXPA97004043A MXPA97004043A (es) 1998-02-01
MX9704043A true MX9704043A (es) 1998-02-28

Family

ID=23368363

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9704043A MX9704043A (es) 1994-12-01 1995-11-30 Surtido de farmaco de liberacion sostenida empleando una goma de hidrocoloide en polvo obtenible a partir de plantas superiores.

Country Status (9)

Country Link
EP (1) EP0793485A4 (es)
JP (1) JPH10509981A (es)
CN (1) CN1172429A (es)
AU (1) AU709413B2 (es)
CA (1) CA2205351A1 (es)
FI (1) FI972304A (es)
MX (1) MX9704043A (es)
NO (1) NO972486L (es)
WO (1) WO1996016638A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811388A (en) * 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
IL119627A (en) * 1996-11-17 2002-03-10 Yissum Res Dev Co PHARMACEUTICAL PREPARATIONS FOR THE CONTROLLED-RELEASE OF AN ACTIVE AGENT COMPRISING AT LEAST ONE β-LACTAM ANTIBIOTIC AGENT
US6210710B1 (en) * 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
EP0987020A1 (en) * 1998-09-04 2000-03-22 Pharma Pass LLC Metoprolol composition and processes for manufacturing the same
EP0974343B1 (en) * 1998-07-22 2004-09-29 Pharma Pass II LLC Process for manufacturing a solid metoprolol composition
SE0003125D0 (sv) * 2000-09-05 2000-09-05 Astrazeneca Ab Modified polymers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1327938A (en) * 1969-12-17 1973-08-22 Sucrest Corp Composition for use in forming tablets
DE2130545A1 (de) * 1971-06-19 1972-12-21 Merck Patent Gmbh Pharmazeutischer Formkoerper
CH630257A5 (en) * 1975-03-17 1982-06-15 Hoffmann La Roche Sustained release formulation
DK130287D0 (da) * 1987-03-13 1987-03-13 Benzon As Alfred Oralt praeparat
US5169639A (en) * 1988-09-19 1992-12-08 Edward Mendell Co., Inc. Controlled release verapamil tablets
JP2628231B2 (ja) * 1992-12-30 1997-07-09 エフ エム シー コーポレーション 放出調整賦形剤として容易に入手できるコンニャクグルコマンナン

Also Published As

Publication number Publication date
EP0793485A4 (en) 1998-08-26
WO1996016638A1 (en) 1996-06-06
CN1172429A (zh) 1998-02-04
FI972304A0 (fi) 1997-05-30
JPH10509981A (ja) 1998-09-29
CA2205351A1 (en) 1996-06-06
EP0793485A1 (en) 1997-09-10
FI972304A (fi) 1997-05-30
AU4372096A (en) 1996-06-19
AU709413B2 (en) 1999-08-26
NO972486L (no) 1997-07-31
NO972486D0 (no) 1997-05-30

Similar Documents

Publication Publication Date Title
AU7643591A (en) A pharmaceutical preparation
UA41995C2 (uk) Лікарська форма азитроміцину з контрольованим вивільненням ( варіанти ), спосіб її введення, спосіб її виготовлення і спосіб лікування інфекційних захворювань ссавців з її використанням ( варіанти )
UA29507C2 (uk) Фармацевтична композиція для інгаляції та спосіб її одержання
ES8500740A1 (es) Un metodo para la preparacion de una forma posologica unitaria solida, terapeuticamente activa, con pauta de liberacion regular y prolongada al ser administrada.
CA2125685A1 (en) Powders for inhalation and process for preparing them
IL111400A0 (en) Pharmaceutical compositions containing metroprolol and methods for the preparation thereof
ZA966067B (en) New pharmaceutical dosage formulations of fenofibrate and their applications
CA2227887A1 (en) Pharmaceutical compositions of conjugated estrogens and methods for their use
EP0776660A3 (en) Long-lasting release nifedipine preparation
WO1995001782A3 (en) Method for making freeze dried drug dosage forms
CA2330480A1 (en) Controlled release formulation of divalproex sodium
AU5257793A (en) Compositions of L-DOPA esters
AU4893790A (en) Nifedipine-containing pharmaceutical compositions and process for the preparation thereof
HU900638D0 (en) Process for preparing modified gembifrozil preparations with retard release
AU3608295A (en) Process of making dosage units by wet granulation
KR100257803B1 (en) Stable hydrated cephalosporin dry powder for oral suspension formulation
ZA967880B (en) Compositions and methods for inhibition of the patho-physiologic actions in mammals in tumor necrosis facto-alpha
BG105436A (en) Pharmaceutical compositions comprising entacapone or nitecapone as well as a cross-linked cellulpse derivative
GR3030256T3 (en) Pellets
HK1023508A1 (en) Stabilized tibolone compositions.
MX9704043A (es) Surtido de farmaco de liberacion sostenida empleando una goma de hidrocoloide en polvo obtenible a partir de plantas superiores.
NZ513981A (en) Delivery of microparticle formulations using needleless syringe device for sustained-release of bioactive compounds
HK1004529A1 (en) Pharmaceutical composition
CA2033418A1 (en) Pharmaceutical preparation for oral administration in fluid form
DE1292303T1 (de) Eine stabile pharmazeutische formulierung die torsemid modifikation ii enthält